← Browse by Condition
Medical Condition

tnbc

Total Trials
3
Recruiting Now
3
Trial Phases
Phase 1, Phase 2

ClinicalMetric tracks all active clinical trials for tnbc sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — tnbc Clinical Trials

How many clinical trials are currently recruiting for tnbc?
ClinicalMetric currently tracks 3 actively recruiting clinical trials for tnbc, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 3. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for tnbc?
tnbc research spans Phase 1 (1 trial), Phase 2 (2 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a tnbc clinical trial?
Eligibility criteria for tnbc trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
1
Phase 2
2
Top Sponsors
Jiangsu Hansoh Pharmaceutical Co., Ltd. 1 trial
Cedars-Sinai Medical Center 1 trial
Fudan University 1 trial

Recruiting Clinical Trials

NCT06769425 Phase 1
Recruiting
HS-10502 Combination Treatment in Patients With Advanced Solid Tumors
Enrollment
157 pts
Location
China
Sponsor
Jiangsu Hansoh Pharmaceutical ...
View Trial →
NCT07017673 Phase 2
Recruiting
Phase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Patients With Early-Stage Triple Negative Breast Cancer
Enrollment
34 pts
Location
United States
Sponsor
Cedars-Sinai Medical Center
View Trial →
NCT07623577 Phase 2
Recruiting
Sac-TMT Combined With Bevacizumab in TNBC With Brain Metastases
Enrollment
24 pts
Location
China
Sponsor
Fudan University
View Trial →

Related Conditions

recurrent ovarian cancer (1) her2 negative (1) advanced breast cancer (1) advanced prostate cancer (1) advanced gastric cancer (1) tnbc triple negative breast cancer (1) early stage triple negative breast carcinoma (1) brain metastasis (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: November 2026  ·  Data Methodology